Safety profile of preoperative administration of LMWH on minimally invasive lung cancer surgery: a randomized controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040547

Enrollment

Unknown

Registered

2020-12-01

Start date

2017-06-01

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thromboembolism

Interventions

preoperative LMWH-administration group:low-molecular-weight-heparin 4000IU, qd, upon admission

postoperative LMWH-administration group:low-molecular-weight-heparin 4000IU, qd,, from postoperative day 1

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–75 years old without any preoperative VTEs (both VTE history and current screening); 2. patients intended for video-assisted thoracoscopic major thoracic surgery (including lobectomy and sublobectomy); 3. patients diagnosed primary lung cancer pathologically.

Exclusion criteria

Exclusion criteria: 1. patients with coagulation disorders: preoperative international normalized ratio (INR) >1.5, or blood platelet count 500ml owing to vessels rupture; 6. patients rejected to continue the study at any point of the study; 7. patients suffering menstruation perioperatively.

Design outcomes

Primary

Measure	Time frame
coagulation function;perioperative bleeding;postoperative chest tube drainage;bleeding related reoperation;	—

Countries

China

Contacts

Public ContactYi-Dan Lin

West China Hospital, Sichuan University

1956296501@qq.com+86 18980602136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 22, 2026